Tags

Type your tag names separated by a space and hit enter

Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease.
Clin Gastroenterol Hepatol 2005; 3(2):122-32CG

Abstract

BACKGROUND & AIMS

Crohn's disease causes an increase in osteopenia and osteoporosis. This study assessed the efficacy of adding etidronate to calcium and vitamin D supplementation for treatment of low bone mineral density in Crohn's disease.

METHODS

One hundred fifty-four patients with Crohn's disease with decreased bone mineral density, determined by using dual-energy x-ray absorptiometry, were randomly assigned to receive etidronate (400 mg orally) or not for 14 days; both groups were then given daily calcium (500 mg) and vitamin D (400 IU) supplementation for 76 days. This cycle was repeated 8 times during a period of 24 months. Biochemical characteristics and bone mineral densities were assessed at 6, 12, and 24 months.

RESULTS

After 24 months bone mineral density significantly increased from baseline in both the etidronate- and the non-etidronate-treated groups (both groups receiving calcium and vitamin D supplementation) at the lumbar spine (P < .001), ultradistal radius (P < .001), and trochanter (P = .004) sites, but not at the total hip. The increase in bone mineral density was similar in each treatment group. No bone mineral density differences were found when groups were analyzed according to gender, corticosteroid use, bone mineral density at baseline, or age.

CONCLUSIONS

Low bone mineral density is frequently associated with Crohn's disease. Supplementation with daily calcium and vitamin D is associated with increases in bone mineral density. The addition of oral etidronate does not further enhance bone mineral density.

Authors+Show Affiliations

Division of Gastroenterology, University of Alberta, Edmonton, Canada.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15704046

Citation

Siffledeen, Jesse S., et al. "Randomized Trial of Etidronate Plus Calcium and Vitamin D for Treatment of Low Bone Mineral Density in Crohn's Disease." Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association, vol. 3, no. 2, 2005, pp. 122-32.
Siffledeen JS, Fedorak RN, Siminoski K, et al. Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease. Clin Gastroenterol Hepatol. 2005;3(2):122-32.
Siffledeen, J. S., Fedorak, R. N., Siminoski, K., Jen, H., Vaudan, E., Abraham, N., ... Greenberg, G. (2005). Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease. Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association, 3(2), pp. 122-32.
Siffledeen JS, et al. Randomized Trial of Etidronate Plus Calcium and Vitamin D for Treatment of Low Bone Mineral Density in Crohn's Disease. Clin Gastroenterol Hepatol. 2005;3(2):122-32. PubMed PMID: 15704046.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease. AU - Siffledeen,Jesse S, AU - Fedorak,Richard N, AU - Siminoski,Kerry, AU - Jen,Ho, AU - Vaudan,Eric, AU - Abraham,Neena, AU - Steinhart,Hillary, AU - Greenberg,Gordon, PY - 2005/2/11/pubmed PY - 2005/6/4/medline PY - 2005/2/11/entrez SP - 122 EP - 32 JF - Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association JO - Clin. Gastroenterol. Hepatol. VL - 3 IS - 2 N2 - BACKGROUND & AIMS: Crohn's disease causes an increase in osteopenia and osteoporosis. This study assessed the efficacy of adding etidronate to calcium and vitamin D supplementation for treatment of low bone mineral density in Crohn's disease. METHODS: One hundred fifty-four patients with Crohn's disease with decreased bone mineral density, determined by using dual-energy x-ray absorptiometry, were randomly assigned to receive etidronate (400 mg orally) or not for 14 days; both groups were then given daily calcium (500 mg) and vitamin D (400 IU) supplementation for 76 days. This cycle was repeated 8 times during a period of 24 months. Biochemical characteristics and bone mineral densities were assessed at 6, 12, and 24 months. RESULTS: After 24 months bone mineral density significantly increased from baseline in both the etidronate- and the non-etidronate-treated groups (both groups receiving calcium and vitamin D supplementation) at the lumbar spine (P < .001), ultradistal radius (P < .001), and trochanter (P = .004) sites, but not at the total hip. The increase in bone mineral density was similar in each treatment group. No bone mineral density differences were found when groups were analyzed according to gender, corticosteroid use, bone mineral density at baseline, or age. CONCLUSIONS: Low bone mineral density is frequently associated with Crohn's disease. Supplementation with daily calcium and vitamin D is associated with increases in bone mineral density. The addition of oral etidronate does not further enhance bone mineral density. SN - 1542-3565 UR - https://www.unboundmedicine.com/medline/citation/15704046/Randomized_trial_of_etidronate_plus_calcium_and_vitamin_D_for_treatment_of_low_bone_mineral_density_in_Crohn's_disease_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1542356504006639 DB - PRIME DP - Unbound Medicine ER -